Eiger Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Cash & Equivalents	25.44	25.8	22.22	28.86	39.37	61.26	32.04	27.76	4.78	14.44	Upgrade
Short-Term Investments	0	73.15	66.59	99.98	55.62	39.09	9.74	32.18	0	70.51	Upgrade
Cash & Cash Equivalents	25.44	98.95	88.82	128.84	94.99	100.35	41.78	59.94	4.78	84.95	Upgrade
Cash Growth	-74.29%	11.41%	-31.07%	35.63%	-5.34%	140.20%	-30.29%	1154.42%	-94.38%	362.43%	Upgrade
Receivables	1.68	1.75	2.58	0	0	0	0	0	0	0	Upgrade
Inventory	1.56	2.85	2.61	0.09	0	0	0	0	0	0	Upgrade
Other Current Assets	9.16	13.99	9.36	8.87	5.39	1.49	0.71	0.58	0.72	3.14	Upgrade
Total Current Assets	37.84	117.54	103.36	137.81	100.38	101.85	42.49	60.52	5.5	88.08	Upgrade
Property, Plant & Equipment	0.63	0.7	1.27	1.89	2.24	0.17	0.08	0.08	0.04	0.76	Upgrade
Long-Term Investments	0	0	17.26	0	0	0	0	0	0	0	Upgrade
Other Long-Term Assets	0.36	1.91	4.51	3.9	2.51	0.44	0.31	0.14	0.05	0.26	Upgrade
Total Long-Term Assets	0.99	2.6	23.04	5.79	4.76	0.6	0.39	0.22	0.09	1.03	Upgrade
Total Assets	38.83	120.14	126.4	143.59	105.14	102.45	42.88	60.74	5.58	89.11	Upgrade
Accounts Payable	2.12	8.98	7.77	4.64	6.41	5.83	3.18	2.64	1.94	6.53	Upgrade
Current Debt	41.2	0.49	8.44	0.58	0.53	0	2	0	5.44	0	Upgrade
Other Current Liabilities	9.97	15.66	13.7	11.41	10	4.19	2.08	2.65	1.01	0.07	Upgrade
Total Current Liabilities	53.28	25.12	29.9	16.63	16.95	10.02	7.27	5.29	8.39	6.61	Upgrade
Long-Term Debt	0	39.71	24.1	31.93	31.71	25.62	13.09	14.73	0	0	Upgrade
Other Long-Term Liabilities	0	0	0	0	0	0.21	0	0	2.34	10.4	Upgrade
Total Long-Term Liabilities	0	39.71	24.1	31.93	31.71	25.83	13.09	14.73	2.34	10.4	Upgrade
Total Liabilities	53.28	64.83	54	48.56	48.66	35.86	20.36	20.02	10.73	17.01	Upgrade
Total Debt	41.2	40.2	32.54	32.51	32.24	25.62	15.09	14.73	5.44	0	Upgrade
Debt Growth	2.50%	23.54%	0.08%	0.84%	25.85%	69.75%	2.49%	170.52%	544300.00%	-99.90%	Upgrade
Retained Earnings	-512.16	-437.19	-340.42	-306.5	-241.45	-171.2	-118.81	-76.36	-29.27	-146.44	Upgrade
Comprehensive Income	-0.17	-0.3	-0.15	-0.01	0.04	-0.03	-0	-0.02	0	-0.01	Upgrade
Shareholders' Equity	-14.46	55.31	72.4	95.04	56.48	66.59	22.52	40.72	-5.15	72.1	Upgrade
Net Cash / Debt	-15.76	58.75	56.28	96.33	62.75	74.73	26.69	45.21	-0.67	84.95	Upgrade
Net Cash / Debt Growth	-	4.39%	-41.58%	53.51%	-16.03%	180.05%	-40.97%	-	-	390.29%	Upgrade
Net Cash Per Share	-10.68	42.34	49.74	102.68	82.62	164.44	91.73	225.78	-93.26	13145.62	Upgrade
Working Capital	-15.45	92.41	73.46	121.18	83.44	91.82	35.22	55.23	-2.9	81.48	Upgrade
Book Value Per Share	-9.79	39.86	63.99	101.30	74.36	146.53	77.41	203.37	-721.47	11158.73	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).